Schedule M to be Made Mandatory for MSME Pharma Firms: Health Minister Mandaviya

India’s small drugmakers in the micro, small, and medium enterprises (MSME) sector will soon be required to adhere to the good manufacturing practices outlined in Schedule M of the Drugs and Cosmetics Act. Health Minister Mansukh Mandaviya announced this decision after engaging with industry representatives, emphasizing the need for quality assurance and reducing compliance burdens. The move aims to uphold India’s reputation as the world’s pharmacy by ensuring the highest standards in drug manufacturing.

Phase-wise Implementation of Schedule M:

    • The adherence to Schedule M practices will be implemented gradually in MSME pharma firms.
    • Schedule M covers various aspects, including shop floors, quality control systems, labs, production, equipment cleaning, and housekeeping.

Enhancing Quality Assurance and Reducing Compliance Burden:

    • The mandatory compliance with Schedule M will improve quality assurance in the production of medicines.
    • Health Minister Mandaviya believes that self-regulation and adherence to good manufacturing practices are crucial for MSME pharma companies.

Safeguarding India’s Pharmaceutical Reputation:

    • India’s position as the “pharmacy of the world” must be upheld.
    • The health ministry is taking measures to prevent compromises in the quality of medicines produced in India.
    • Recent incidents of deaths allegedly caused by drugs made in India highlight the importance of maintaining high standards.

Workshops and Stringent Actions:

    • The central government conducted a workshop in Hyderabad with state drug regulators to expedite policy implementation.
    • The Drugs Controller General of India has been instructed to take strict action against manufacturers of spurious drugs.
    • The government has zero tolerance for non-compliance and the production of substandard medicines.

Risk-based Inspections and Regulatory Measures:

    • Regulatory authorities have initiated risk-based inspections and audits of pharmaceutical manufacturing units.
    • Actions have been taken against firms found to violate quality compliance.
    • Production has been halted at certain firms, while licenses have been canceled or suspended.
    • Show cause notices and warning letters have been issued to other non-compliant companies.

Find More Business News Here

 

 

Piyush Shukla

Recent Posts

Who Presides over the Lok Sabha Meetings?

The Lok Sabha is the lower house of India's Parliament, where important discussions and decisions…

1 hour ago

New Appointment Process for India’s Election Commissioners

The appointment procedure for India's Chief Election Commissioner (CEC) and Election Commissioners (ECs) has undergone…

2 hours ago

Top-5 Plum Producing States of India, Know Their Names

Plums are sweet and juicy fruits loved by many people in India. They are not…

2 hours ago

APAAR ID Registration, Full Form, Benefits, and Download

What Is APAAR ID? The Ministry of Education and Government of India has initiated the…

2 hours ago

Difference Between Metallic Minerals and Non-Metallic Minerals

Minerals are natural substances found in the Earth, and they are essential for various human…

3 hours ago

Top-10 Indian Cities with the Best AQI 2025, Check the List

In 2025, several cities in India have made significant improvements in air quality, offering cleaner…

4 hours ago